Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03179800 · ClinicalTrials.gov registry record · NA

CALM- 2 - Controlling and Lowering Blood Pressure With the MobiusHD™

A NA study of Hypertension and Resistant Hypertension, sponsored by Vascular Dynamics.

Active
Registry status
NA
Development phase
300
Enrollment target
6
Study locations

NCT03179800: Active NA study of Hypertension and Resistant Hypertension, sponsored by Vascular Dynamics.

NCT03179800 is a NA study of Hypertension and Resistant Hypertension that is active but no longer recruiting, run by Vascular Dynamics. The registered enrollment target is 300 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (91% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03179800, a NA study of Hypertension and Resistant Hypertension, is active but no longer recruiting, sponsored by Vascular Dynamics.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
300 participants
Enrollment target
6
Study locations

Study Summary

The objective of this study is to evaluate the safety and effectiveness of the MobiusHD System in a prospective, randomized, double-blind, sham-controlled multi-center pivotal study.

Interventions

  • DEVICE MobiusHD
  • OTHER Sham Implantation

Study Locations (6)

Georgia

  • Emory University Hospital Midtown - Atlanta

Illinois

  • Southern Illinois University - Springfield

Indiana

  • St. Vincent Heart Center of Indiana - Indianapolis

Louisiana

  • Ochsner Medical Center - New Orleans

Ohio

  • The Carl & Edyth Lindner Center for Research & Education at The Christ Hospital - Cincinnati

Other

  • CHU Nancy Centre Coeur et Vaisseaux - Nancy

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2017-10-19
Est. Completion 2025-05
Phase NA
Vascular Dynamics

2 total trials

What the registry record for NCT03179800 still lists

NCT03179800 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (91% lower).

The record links to 2 conditions, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which MobiusHD is the first listed.

NCT03179800 lists 6 locations in 6 states (Georgia, Illinois, Indiana).

Frequently Asked Questions

What is clinical trial NCT03179800 about?

NCT03179800 is a clinical study titled "CALM- 2 - Controlling and Lowering Blood Pressure With the MobiusHD™". The objective of this study is to evaluate the safety and effectiveness of the MobiusHD System in a prospective, randomized, double-blind, sham-controlled multi-center pivotal study.

What is the current status of trial NCT03179800?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 300 participants. The study started on 2017-10-19. Estimated completion is 2025-05.

What conditions does trial NCT03179800 study?

This clinical trial studies the following conditions: Hypertension, Resistant Hypertension.

What interventions are being tested in trial NCT03179800?

The interventions under investigation include: MobiusHD (DEVICE), Sham Implantation (OTHER).

Who is sponsoring clinical trial NCT03179800?

This trial is sponsored by Vascular Dynamics, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03179800 being conducted?

This trial has 6 study locations across Georgia, Illinois, Indiana, Louisiana, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03179800's enrollment target sits among peer trials

300 170th of 470 higher than 291 of 470 other Hypertension trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00353483 · 300 participants

    Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

  • NCT00588185 · 300 participants · NA

    [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

  • NCT00682032 · 300 participants · NA

    The Effect of Beta-glucan in Non-Small Cell Lung Cancer

  • NCT00870064 · 300 participants · NA

    The Treatment of Type I Open Fractures in Pediatrics

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03179800, the US trial registry maintained by the National Library of Medicine. NCT03179800 (mid enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.